Page 59 - Read Online

Page 183 Kamal et al. J Transl Genet Genom 2024;8:162-85 https://dx.doi.org/10.20517/jtgg.2023.55

94. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and
applications. Microbiol Mol Biol Rev 2003;67:657-85. DOI PubMed PMC
95. Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-
forward regulation of beta-secretase. Nat Med 2008;14:723-30. DOI PubMed PMC
96. Johnson R. Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis 2012;46:245-54. DOI PubMed
97. Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A. Neural plasticity in multiple sclerosis: the functional and molecular background.
Neural Plast 2015;2015:307175. DOI PubMed PMC
98. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of
anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004;24:4250-8. DOI PubMed PMC
99. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled
neuronal genes. Nat Genet 2003;35:76-83. DOI
100. Ghafouri-Fard S, Khoshbakht T, Taheri M, Ghanbari M. A concise review on the role of BDNF-AS in human disorders. Biomed
Pharmacother 2021;142:112051. DOI
101. Yin X, Wang S, Ge R, et al. Long non-coding RNA DNMBP-AS1 promotes prostate cancer development by regulating LCLAT1.
Syst Biol Reprod Med 2023;69:142-52. DOI
102. Zhang W, Shi C, Xu Q, Chen X, Zhu H, Zheng B. Long non-coding RNA MIR22HG suppresses cell proliferation and promotes
apoptosis in prostate cancer cells by sponging microRNA-9-3p. Bioengineered 2022;13:13108-17. DOI PubMed PMC
103. Ren Y, Jia HH, Xu YQ, et al. Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-ß
1 secretion. Mol Cancer 2018;17:5. DOI PubMed PMC
104. Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. Nat Biotechnol 2017;35:249-63. DOI
PubMed PMC
105. Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis 2022;13:644. DOI PubMed
PMC
106. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug
Discov 2021;20:629-51. DOI PubMed PMC
107. Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today 2017;22:823-33.
DOI PubMed
108. Migliorati JM, Liu S, Liu A, et al. Absorption, distribution, metabolism, and excretion of US food and drug administration-approved
antisense oligonucleotide drugs. Drug Metab Dispos 2022;50:888-97. DOI PubMed
109. Germain ND, Chung WK, Sarmiere PD. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases. Mol
Aspects Med 2023;91:101148. DOI PubMed
110. Sheng P, Flood KA, Xie M. Short hairpin RNAs for strand-specific small interfering RNA production. Front Bioeng Biotechnol
2020;8:940. DOI PubMed PMC
111. Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-64. DOI PubMed
PMC
112. Lima JF, Cerqueira L, Figueiredo C, Oliveira C, Azevedo NF. Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA
Biol 2018;15:338-52. DOI PubMed PMC
113. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A. Generation of miRNA sponge
constructs. Methods 2012;58:113-7. DOI PubMed
114. Chang S. Construction of multi-potent microRNA sponge and its functional evaluation. In: Wu W, editor. MicroRNA and cancer.
New York: Springer; 2018. pp. 201-9. DOI
115. Jung J, Yeom C, Choi YS, et al. Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge.
Oncotarget 2015;6:20370-87. DOI PubMed PMC
116. Das S, Kohr M, Dunkerly-Eyring B, et al. Divergent effects of miR-181 family members on myocardial function through protective
cytosolic and detrimental mitochondrial microRNA targets. J Am Heart Assoc 2017;6:e004694. DOI PubMed PMC
117. Wang Z. The Principles of MiRNA-masking antisense oligonucleotides technology. In: Wu W, editor. MicroRNA and cancer.
Totowa: Humana Press; 2011. pp. 43-9. DOI
118. Gilot D, Migault M, Bachelot L, et al. A non-coding function of TYRP1 mRNA promotes melanoma growth. Nat Cell Biol
2017;19:1348-57. DOI
119. Almarghalani DA, Boddu SHS, Ali M, et al. Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and
progress in drug delivery systems. Neural Regen Res 2022;17:1717-25. DOI PubMed PMC
120. Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs 2022;36:549-71. DOI PubMed PMC
121. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell
Biol 2021;22:96-118. DOI
122. Modarresi F, Faghihi MA, Lopez-Toledano MA, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific
transcriptional upregulation. Nat Biotechnol 2012;30:453-9. DOI PubMed PMC
123. Lee D, Chen W, Kaku HN, et al. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult
mouse models of Angelman syndrome. Elife 2023;12:e81892. DOI
124. de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.